HHT + IPI-504 synergistically inhibit major targets and oncogenic signaling pathways. (A-D) Western blots exhibiting expression levels of total FLT3, phosphorylated FLT3 (pFLT3) and its downstream signaling proteins or targets in MV4-11, MOLM-13 or primary sample treated with vehicle, HHT (8 nM) and/or IPI504 (0.8 μM) for (A, C and D) 24 hours and (B) 6 hours, with GAPDH or β-actin being the loading control.